US6048729A
(en)
*
|
1987-05-01 |
2000-04-11 |
Transkaryotic Therapies, Inc. |
In vivo protein production and delivery system for gene therapy
|
US6555370B1
(en)
|
1990-11-13 |
2003-04-29 |
Immunex Corporation |
Bifunctional selectable fusion genes
|
PT101031B
(pt)
|
1991-11-05 |
2002-07-31 |
Transkaryotic Therapies Inc |
Processo para o fornecimento de proteinas por terapia genetica
|
US6692737B1
(en)
|
1991-11-05 |
2004-02-17 |
Transkaryotic Therapies, Inc. |
In vivo protein production and delivery system for gene therapy
|
US6054288A
(en)
*
|
1991-11-05 |
2000-04-25 |
Transkaryotic Therapies, Inc. |
In vivo protein production and delivery system for gene therapy
|
US5641670A
(en)
*
|
1991-11-05 |
1997-06-24 |
Transkaryotic Therapies, Inc. |
Protein production and protein delivery
|
US6063630A
(en)
|
1991-11-05 |
2000-05-16 |
Transkaryotic Therapies, Inc. |
Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
|
US5968502A
(en)
*
|
1991-11-05 |
1999-10-19 |
Transkaryotic Therapies, Inc. |
Protein production and protein delivery
|
WO1993010218A1
(en)
*
|
1991-11-14 |
1993-05-27 |
The United States Government As Represented By The Secretary Of The Department Of Health And Human Services |
Vectors including foreign genes and negative selective markers
|
US6670178B1
(en)
|
1992-07-10 |
2003-12-30 |
Transkaryotic Therapies, Inc. |
In Vivo production and delivery of insulinotropin for gene therapy
|
US6531124B1
(en)
|
1992-07-10 |
2003-03-11 |
Transkaryotic Therapies, Inc. |
In vivo production and delivery of insulinotropin for gene therapy
|
CA2159898A1
(en)
|
1993-04-06 |
1994-10-13 |
Stephen D. Lupton |
Hybrid genes for use in the production of t h-independent cytotoxic t cells
|
WO1994028143A1
(en)
*
|
1993-05-21 |
1994-12-08 |
Targeted Genetics Corporation |
Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
|
IT1261847B
(it)
*
|
1993-09-01 |
1996-06-03 |
San Romanello Centro Fond |
Metodo per marcare cellule eucariote.
|
US5827642A
(en)
*
|
1994-08-31 |
1998-10-27 |
Fred Hutchinson Cancer Research Center |
Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
|
WO1996013584A1
(en)
*
|
1994-11-01 |
1996-05-09 |
Targeted Genetics Corporation |
Chimeric receptors for the generation of selectively-activatable th-independent cytotoxic t cells
|
AT403167B
(de)
*
|
1994-11-14 |
1997-11-25 |
Immuno Ag |
Selektion und expression von fremdproteinen mittels eines selektions-amplifikations-systems
|
US6924128B2
(en)
|
1994-12-06 |
2005-08-02 |
Targeted Genetics Corporation |
Packaging cell lines for generation of high titers of recombinant AAV vectors
|
US6752987B1
(en)
|
1995-02-28 |
2004-06-22 |
The Regents Of The University Of California |
Adenovirus encoding human adenylylcyclase (AC) VI
|
US6306830B1
(en)
|
1996-09-05 |
2001-10-23 |
The Regents Of The University Of California |
Gene therapy for congestive heart failure
|
CA2188575A1
(en)
|
1995-02-28 |
1996-09-06 |
H. Kirk Hammond |
Gene transfer-mediated angiogenesis therapy
|
US5686120A
(en)
*
|
1995-05-22 |
1997-11-11 |
Wisconsin Alumni Research Foundation |
Pre-mRNA processing enhancer and method for intron-independent gene expression
|
US5910434A
(en)
*
|
1995-12-15 |
1999-06-08 |
Systemix, Inc. |
Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
|
IL125884A0
(en)
*
|
1996-03-04 |
1999-04-11 |
Targeted Genetics Corp |
Modified rapid expansion methods ("modified-rem") for in vitro propagation of t lymphocytes
|
EP0904350B1
(de)
|
1996-03-04 |
2010-08-04 |
Calyx Bio-Ventures Inc. |
Modifizierte schnellvermehrungsmethode ('modified-rem') zur in vitro vermehrung von t-lymphozyten
|
US6268214B1
(en)
|
1996-04-04 |
2001-07-31 |
Roche Diagnostics Gmbh |
Vectors encoding a modified low affinity nerve growth factor receptor
|
US6642051B1
(en)
|
1997-10-21 |
2003-11-04 |
Targeted Genetics Corporation |
Amplifiable adeno-associated virus(AAV) packaging cassettes for the production of recombinant AAV vectors
|
US6893865B1
(en)
|
1999-04-28 |
2005-05-17 |
Targeted Genetics Corporation |
Methods, compositions, and cells for encapsidating recombinant vectors in AAV particles
|
EP1255822A2
(de)
|
1999-12-27 |
2002-11-13 |
The Regents Of The University Of California |
Modifizierte adenylylcyclase vom typ vi für gentheraphie bei congestiven herzkrankheiten
|
US20050271639A1
(en)
|
2002-08-22 |
2005-12-08 |
Penn Marc S |
Genetically engineered cells for therapeutic applications
|
US20040037811A1
(en)
|
2002-08-22 |
2004-02-26 |
The Cleveland Clinic Foundation |
Stromal cell-derived factor-1 mediates stem cell homing and tissue regeneration in ischemic cardiomyopathy
|
US20140170116A9
(en)
|
2002-08-22 |
2014-06-19 |
Marc S. Penn |
Method of treating ischemic disorders
|
US7344886B2
(en)
|
2002-11-29 |
2008-03-18 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
Neomycin-phosphotransferase-genes and methods for the selection of recombinant cells producing high levels of a desired gene product
|
US7384744B2
(en)
|
2002-11-29 |
2008-06-10 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products
|
DE10338531A1
(de)
|
2003-08-19 |
2005-04-07 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Reklonierung von Produktionszellen
|
US8669109B2
(en)
|
2003-08-19 |
2014-03-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Methods of producing proteins in Chinese hamster ovary (CHO) cells
|
US20070003528A1
(en)
|
2005-06-29 |
2007-01-04 |
Paul Consigny |
Intracoronary device and method of use thereof
|
US20070036770A1
(en)
|
2005-08-12 |
2007-02-15 |
Wagner Darrell O |
Biologic device for regulation of gene expression and method therefor
|
TW200732472A
(en)
|
2005-10-21 |
2007-09-01 |
Hoffmann La Roche |
Method for the recombinant expression of a polypeptide
|
US7892790B2
(en)
|
2005-10-28 |
2011-02-22 |
Hoffmann-La Roche Inc. |
Protein expression in rodent cells
|
EP1976567B1
(de)
|
2005-12-28 |
2020-05-13 |
The Scripps Research Institute |
Natürliche antisense- und nicht-kodierende rna-transkripte als arzneitargets
|
US20070190028A1
(en)
|
2006-02-13 |
2007-08-16 |
Jihong Qu |
Method and apparatus for heat or electromagnetic control of gene expression
|
ES2543629T3
(es)
|
2006-05-17 |
2015-08-20 |
Hoffmann-La Roche Ag |
Células productoras de polipéptidos
|
US20080124760A1
(en)
|
2006-07-26 |
2008-05-29 |
Barbara Enenkel |
Regulatory Nucleic Acid Elements
|
US20080131415A1
(en)
|
2006-11-30 |
2008-06-05 |
Riddell Stanley R |
Adoptive transfer of cd8 + t cell clones derived from central memory cells
|
WO2008103475A1
(en)
|
2007-02-20 |
2008-08-28 |
Anaptysbio, Inc. |
Somatic hypermutation systems
|
CL2008000707A1
(es)
|
2007-03-13 |
2008-09-22 |
Hoffmann La Roche |
Conjugado de polipeptidos antifusogenicos y polipeptidos derivados de la cabeza globular del factor del complemento c1q; composicion farmaceutica que lo comprende; su uso para tratar infecciones viricas; y metodo de produccion.
|
GB0706631D0
(en)
*
|
2007-04-04 |
2007-05-16 |
King S College London |
Nucleic acids and libraries
|
PT2167540T
(pt)
|
2007-06-29 |
2018-04-04 |
Hoffmann La Roche |
Mutante na cadeia pesada que conduz a uma produção melhorada de imunoglobulina
|
KR101280704B1
(ko)
|
2007-10-12 |
2013-07-01 |
에프. 호프만-라 로슈 아게 |
다수의 핵산으로부터의 단백질 발현
|
CA2709398C
(en)
|
2007-12-14 |
2017-11-07 |
The Cleveland Clinic Foundation |
Use of stromal cell-derived factor 1 for promoting wound healing
|
MX2010012592A
(es)
|
2008-05-20 |
2011-05-05 |
Eos Neuroscience Inc |
Vectores para la administracion de proteinas sensibles a la luz y metodos de uso de las mismas.
|
KR101866152B1
(ko)
|
2008-12-04 |
2018-06-08 |
큐알엔에이, 인크. |
종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료
|
MX2011005912A
(es)
|
2008-12-04 |
2011-06-17 |
Opko Curna Llc |
Tratamiento de enfermedades relacionadas con factor de crecimiento endotelial vascular por inhibicion de transcrito antisentido natural para factor de crecimiento endotelial vascular.
|
KR101829469B1
(ko)
|
2008-12-04 |
2018-03-30 |
큐알엔에이, 인크. |
Epo에 대한 천연 안티센스 전사체의 억제에 의해 에리트로포에틴(epo) 관련된 질환의 치료
|
CA2752237C
(en)
|
2009-02-12 |
2020-03-24 |
Opko Curna, Llc |
Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
|
US9464287B2
(en)
|
2009-03-16 |
2016-10-11 |
Curna, Inc. |
Treatment of nuclear factor (erythroid-derived 2)-like 2 (NRF2) related diseases by inhibition of natural antisense transcript to NRF2
|
WO2010107740A2
(en)
|
2009-03-17 |
2010-09-23 |
Curna, Inc. |
Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1
|
RU2537264C2
(ru)
|
2009-04-03 |
2014-12-27 |
Медикал Рисерч Каунсил |
Мутанты индуцируемой активацией цитидиндеаминазы (aid) и способы их применения
|
KR101722541B1
(ko)
|
2009-05-06 |
2017-04-04 |
큐알엔에이, 인크. |
Ttp에 대한 천연 안티센스 전사체의 억제에 의한 트리스테트라프롤린 관련된 질환의 치료
|
US9155754B2
(en)
|
2009-05-06 |
2015-10-13 |
Curna, Inc. |
Treatment of ABCA1 gene related diseases by inhibition of a natural antisense transcript to ABCA1
|
JP5931720B2
(ja)
|
2009-05-08 |
2016-06-08 |
クルナ・インコーポレーテッド |
Dmdファミリーに対する天然アンチセンス転写物の抑制によるジストロフィンファミリー関連疾患の治療
|
DK2432881T3
(en)
|
2009-05-18 |
2018-02-26 |
Curna Inc |
TREATMENT OF REPROGRAMMING FACTOR-RELATED DISEASES BY INHIBITING NATURAL ANTISENSE TRANSCRIPTS TO A REPROGRAMMING FACTOR
|
EP2432882B1
(de)
|
2009-05-22 |
2019-12-25 |
CuRNA, Inc. |
Behandlung von erkrankungen im zusammenhang mit dem transkriptionsfaktor e3 (tfe3) und dem insulinrezeptorsubstrat 2 (irs2) mittels hemmung des natürlichen antisense-transkripts gegen tfe3
|
WO2010138806A2
(en)
|
2009-05-28 |
2010-12-02 |
Curna, Inc. |
Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
|
CN102612560B
(zh)
|
2009-06-16 |
2017-10-17 |
库尔纳公司 |
通过抑制针对对氧磷酶1(pon1)的天然反义转录物来治疗pon1相关的疾病
|
US20120171170A1
(en)
|
2009-06-16 |
2012-07-05 |
Opko Curna, Llc |
Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
|
JP6073133B2
(ja)
|
2009-06-24 |
2017-02-01 |
クルナ・インコーポレーテッド |
腫瘍壊死因子受容体2(tnfr2)に対する天然アンチセンス転写物の抑制によるtnfr2関連疾患の治療
|
WO2010151674A2
(en)
|
2009-06-26 |
2010-12-29 |
Curna, Inc. |
Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
|
WO2011011700A2
(en)
|
2009-07-24 |
2011-01-27 |
Curna, Inc. |
Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
|
ES2585360T3
(es)
|
2009-08-05 |
2016-10-05 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con un gen de la insulina (INS) por inhibición de la transcripción antisentido natural en un gen de la insulina (INS)
|
ES2599986T3
(es)
|
2009-08-11 |
2017-02-06 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con adiponectina (ADIPOQ) mediante la inhibición de un transcrito antisentido natural de una adiponectina (ADIPOQ)
|
WO2011022606A2
(en)
|
2009-08-21 |
2011-02-24 |
Curna, Inc. |
Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip
|
KR101892760B1
(ko)
|
2009-08-25 |
2018-08-28 |
큐알엔에이, 인크. |
IQGAP에 대한 천연 안티센스 전사체의 억제에 의한 GTPase 활성화 단백질을 함유하는 IQ 모티프(IQGAP)와 관련된 질환의 치료
|
EP2473196B1
(de)
|
2009-08-28 |
2017-05-31 |
The Cleveland Clinic Foundation |
Sdf-1-verabreichung zur behandlung von ischämischem gewebe
|
US8822214B2
(en)
|
2009-09-15 |
2014-09-02 |
Medimmune Limited |
Cells for transient expression and uses thereof
|
WO2011038210A2
(en)
|
2009-09-25 |
2011-03-31 |
Curna, Inc. |
Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity
|
RU2639550C2
(ru)
|
2009-12-16 |
2017-12-21 |
Курна, Инк. |
Лечение заболеваний, связанных с сайт-1 мембраносвязанной пептидазой транскрипционных факторов (mbtps1), путем ингибирования природного антисмыслового транскрипта к mbtps1
|
WO2011079261A2
(en)
|
2009-12-23 |
2011-06-30 |
Curna, Inc. |
Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf
|
WO2011079263A2
(en)
|
2009-12-23 |
2011-06-30 |
Curna, Inc. |
Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2
|
WO2011090741A2
(en)
|
2009-12-29 |
2011-07-28 |
Opko Curna, Llc |
TREATMENT OF TUMOR PROTEIN 63 (p63) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO p63
|
ES2657452T3
(es)
|
2009-12-29 |
2018-03-05 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con el factor respiratorio nuclear 1 (NRF1) mediante inhibición de transcrito antisentido natural a NRF1
|
DK2519632T3
(en)
|
2009-12-31 |
2018-07-23 |
Curna Inc |
TREATMENT OF INSULIN RECEPTOR SUBSTRATE 2- (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPTION TO IRS2 AND TRANSCRIPTION FACTOR E3 (TFE3)
|
WO2011082409A2
(en)
|
2010-01-04 |
2011-07-07 |
Curna, Inc. |
Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8
|
KR101853509B1
(ko)
|
2010-01-06 |
2018-04-30 |
큐알엔에이, 인크. |
췌장 발달 유전자에 대한 천연 안티센스 전사체의 억제에 의한 췌장 발달 유전자와 관련된 질환의 치료
|
ES2664866T3
(es)
|
2010-01-11 |
2018-04-23 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con la globulina fijadora de hormonas sexuales (shbg) mediante inhibición del transcrito antisentido natural a shbg
|
WO2011091390A2
(en)
|
2010-01-25 |
2011-07-28 |
Opko Curna, Llc |
Treatment of rnase h1 related diseases by inhibition of natural antisense transcript to rnase h1
|
US8962586B2
(en)
|
2010-02-22 |
2015-02-24 |
Curna, Inc. |
Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related diseases by inhibition of natural antisense transcript to PYCR1
|
TWI600759B
(zh)
|
2010-04-02 |
2017-10-01 |
可娜公司 |
藉由抑制群落刺激因子3(csf3)之天然反義轉錄物以治療csf3相關疾病
|
US20130225664A1
(en)
|
2010-04-05 |
2013-08-29 |
Alan Horsager |
Methods and compositions for decreasing chronic pain
|
JP5978203B2
(ja)
|
2010-04-09 |
2016-08-24 |
カッパーアールエヌエー,インコーポレイテッド |
Fgf21に対する天然アンチセンス転写物の阻害による線維芽細胞増殖因子(fgf21)線維芽細胞増殖因子fgf21)関連疾患の治療
|
RU2018110642A
(ru)
|
2010-05-03 |
2019-02-27 |
Курна, Инк. |
Лечение заболеваний, связанных с сиртуином (sirt), путем ингибирования природного антисмыслового транскрипта к сиртуину (sirt)
|
TWI531370B
(zh)
|
2010-05-14 |
2016-05-01 |
可娜公司 |
藉由抑制par4天然反股轉錄本治療par4相關疾病
|
NO2576784T3
(de)
|
2010-05-26 |
2018-04-14 |
|
|
EP3299464B1
(de)
|
2010-05-26 |
2019-10-02 |
CuRNA, Inc. |
Behandlung von durch atonal homolog 1 (atoh1) vermittelten erkrankungen durch hemmung des natürlichen antisense-transkripts für atoh1
|
US20110319478A1
(en)
|
2010-06-04 |
2011-12-29 |
Medtronic, Inc. |
Compositions to Treat Cardiac Pacing Conditions
|
US20110305670A1
(en)
|
2010-06-10 |
2011-12-15 |
President And Fellows Of Harvard College |
Nucleic acid encoding fusion polypeptides that prevent or inhibit hiv infection
|
JP6023705B2
(ja)
|
2010-06-23 |
2016-11-09 |
カッパーアールエヌエー,インコーポレイテッド |
ナトリウムチャネル、電位依存性、αサブユニット(SCNA)に対する天然アンチセンス転写物の阻害によるSCNA関連疾患の治療
|
CN103068982B
(zh)
|
2010-07-14 |
2017-06-09 |
库尔纳公司 |
通过抑制盘状大同系物(dlg)的天然反义转录物而治疗dlg相关疾病
|
US20120258496A1
(en)
|
2010-09-27 |
2012-10-11 |
Boehringer Ingelheim International Gmbh |
Production of low fucose antibodies in h4-ii-e rat cells
|
EP2625274B1
(de)
|
2010-10-06 |
2017-07-19 |
CuRNA, Inc. |
Behandlung sialidase-4-(neu4)-vermittelter erkrankungen durch hemmung des natürlichen antisense-transkripts gegen neu4
|
JP6049623B2
(ja)
|
2010-10-22 |
2016-12-21 |
カッパーアールエヌエー,インコーポレイテッド |
α‐L‐イズロニダーゼ(IDUA)への天然アンチセンス転写物の阻害によるIDUA関連疾患の治療
|
US10000752B2
(en)
|
2010-11-18 |
2018-06-19 |
Curna, Inc. |
Antagonat compositions and methods of use
|
JP6071893B2
(ja)
|
2010-11-23 |
2017-02-01 |
カッパーアールエヌエー,インコーポレイテッド |
Nanogへの天然アンチセンス転写物の阻害によるnanog関連疾患の治療
|
ES2653247T3
(es)
|
2011-06-09 |
2018-02-06 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con la frataxina (FXN) mediante inhibición del transcrito antisentido natural al gen FXN
|
EA029151B1
(ru)
|
2011-09-06 |
2018-02-28 |
Курна, Инк. |
ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АЛЬФА-СУБЪЕДИНИЦАМИ ПОТЕНЦИАЛЗАВИСИМЫХ НАТРИЕВЫХ КАНАЛОВ (SCNxA), С ПОМОЩЬЮ МАЛЫХ МОЛЕКУЛ
|
EP2626369A1
(de)
|
2011-11-24 |
2013-08-14 |
Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) |
Gentechnisch veränderte mesenchymale Stammzellen und ihre therapeutische Verwendung
|
WO2013082298A2
(en)
|
2011-11-30 |
2013-06-06 |
Board Of Trustees Of Michigan State University |
Immunological composition for clostridium difficile
|
TR201815503T4
(tr)
|
2012-03-15 |
2018-11-21 |
Curna Inc |
Beyin kaynaklı nörotrofik faktör (bknf) ile ilişkili hastalıkların doğal antisens transkriptinin bknf'ye inhibisyonu ile muamelesi.
|
US9937242B2
(en)
|
2012-04-09 |
2018-04-10 |
Case Western Reserve University |
Compositions and methods for inhibiting the activity of LAR family phosphatases
|
EP2836239A1
(de)
|
2012-04-11 |
2015-02-18 |
The United States of America, as Represented By the Secretary, Department of Health and Human Services |
Chimäre antigenrezeptoren zur anzielung des b-zellen-reifungsantigens
|
TWI698240B
(zh)
|
2012-05-15 |
2020-07-11 |
澳大利亞商艾佛蘭屈澳洲私營有限公司 |
使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
|
US20150140591A1
(en)
|
2012-06-06 |
2015-05-21 |
Boehringer Ingelheim International Gmbh |
CELL ENGINEERING USING RNAs
|
RS61345B1
(sr)
|
2012-08-20 |
2021-02-26 |
Hutchinson Fred Cancer Res |
Postupak i kompozicije za ćelijsku imunoterapiju
|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
WO2014102101A1
(en)
|
2012-12-31 |
2014-07-03 |
Boehringer Ingelheim International Gmbh |
Novel intron sequences
|
WO2014102103A2
(en)
|
2012-12-31 |
2014-07-03 |
Boehringer Ingelheim International Gmbh |
Heterologous intron within a signal peptide
|
WO2014141037A1
(en)
|
2013-03-11 |
2014-09-18 |
Novartis Ag |
Method of screening cell clones
|
US20160331809A1
(en)
|
2013-03-15 |
2016-11-17 |
Juventas Therapeutics, Inc. |
The use of sdf-1 to mitigate scar formation
|
CN105518018B
(zh)
|
2013-03-15 |
2020-04-03 |
细胞基因公司 |
修饰的t淋巴细胞
|
LT2992017T
(lt)
|
2013-05-02 |
2021-02-25 |
Anaptysbio, Inc. |
Antikūnai nukreipti prieš programuotos žūties baltymą-1 (pd-1)
|
LT3027646T
(lt)
|
2013-07-31 |
2018-09-25 |
Novartis Ag |
Nauji atrankos vektoriai ir eukariotinių ląstelių šeimininkių atrankos būdai
|
KR20160079854A
(ko)
|
2013-10-31 |
2016-07-06 |
프레드 헛친슨 켄서 리서치 센터 |
변형된 조혈 줄기/선조 및 비-t 효과기 세포 및 이의 용도
|
CA2934412C
(en)
|
2013-12-20 |
2024-02-20 |
Novartis Ag |
Novel eukaryotic cells and methods for recombinantly expressing a product of interest
|
ES2758504T3
(es)
|
2013-12-20 |
2020-05-05 |
Novartis Ag |
Células eucariotas novedosas y métodos para expresar de forma recombinante un producto de interés
|
EP3092253B1
(de)
|
2014-01-10 |
2021-03-17 |
AnaptysBio, Inc. |
Gegen interleukin-33 (il-33) gerichtete antikörper
|
EP3119798B1
(de)
|
2014-03-17 |
2020-08-05 |
Adverum Biotechnologies, Inc. |
Zusammensetzungen und verfahren zur verbesserten genexpression in zapfenzellen
|
CA2945308C
(en)
|
2014-04-10 |
2023-10-31 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Transgene genetic tags and methods of use
|
MA51794A
(fr)
|
2014-04-23 |
2020-05-06 |
Juno Therapeutics Inc |
Procédés d'isolation, de culture et de modification génétique de populations de cellules immunitaires pour thérapie adoptive
|
MX368664B
(es)
|
2014-04-29 |
2019-10-10 |
Novartis Ag |
Células novedosas de vertebrados y métodos para la expresión recombinante de un polipéptido de interés.
|
CN106536564B
(zh)
|
2014-06-02 |
2021-08-31 |
美国卫生和人力服务部 |
靶向cd-19的嵌合抗原受体
|
CN107075483A
(zh)
|
2014-07-15 |
2017-08-18 |
朱诺治疗学股份有限公司 |
用于过继细胞治疗的工程改造的细胞
|
SG10202104804PA
(en)
|
2014-10-20 |
2021-06-29 |
Juno Therapeutics Inc |
Methods and compositions for dosing in adoptive cell therapy
|
TWI735418B
(zh)
|
2014-11-05 |
2021-08-11 |
美商奇諾治療有限公司 |
用於轉導作用及細胞處理之方法
|
EP3224362A4
(de)
|
2014-11-26 |
2018-06-06 |
The Regents of The University of California |
Therapeutische zusammensetzungen mit transkriptionsfaktoren sowie verfahren zur herstellung und verwendung davon
|
ES2819553T3
(es)
|
2014-12-03 |
2021-04-16 |
Juno Therapeutics Inc |
Métodos y composiciones para terapia celular adoptiva
|
MA41346A
(fr)
|
2015-01-12 |
2017-11-21 |
Juno Therapeutics Inc |
Eléments régulateurs post-transcriptionnels d'hépatite modifiée
|
TWI718118B
(zh)
|
2015-01-16 |
2021-02-11 |
美商奇諾治療有限公司 |
針對ror1之特異性抗體及嵌合抗原受體
|
MA41463A
(fr)
|
2015-02-03 |
2017-12-12 |
Anaptysbio Inc |
Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
|
EA201791939A1
(ru)
|
2015-03-02 |
2018-01-31 |
Адверум Байотекнолоджиз, Инк. |
Композиции и способы интравитреальной доставки полинуклеотидов в колбочки сетчатки
|
MA41867A
(fr)
|
2015-04-01 |
2018-02-06 |
Anaptysbio Inc |
Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3)
|
WO2016168542A1
(en)
|
2015-04-15 |
2016-10-20 |
Anaptysbio, Inc. |
Antibodies directed against interleukin 36 receptor (il-36r)
|
WO2016176651A2
(en)
|
2015-04-29 |
2016-11-03 |
Fred Hutchinson Cancer Research Center |
Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
|
WO2016176652A2
(en)
|
2015-04-29 |
2016-11-03 |
Fred Hutchinson Cancer Research Center |
Modified stem cells and uses thereof
|
MA42895A
(fr)
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
Cellules modifiées pour thérapie cellulaire adoptive
|
WO2017027291A1
(en)
|
2015-08-07 |
2017-02-16 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Bispecific car t-cells for solid tumor targeting
|
EP3147366A1
(de)
|
2015-09-25 |
2017-03-29 |
Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts |
Todesrezeptorbasierter selektionsmarker
|
MA45489A
(fr)
|
2015-10-22 |
2018-08-29 |
Juno Therapeutics Gmbh |
Procédés de culture de cellules, kits et appareil associés
|
MA45488A
(fr)
|
2015-10-22 |
2018-08-29 |
Juno Therapeutics Gmbh |
Procédés, kits et appareil de culture de cellules
|
WO2017079703A1
(en)
|
2015-11-05 |
2017-05-11 |
Juno Therapeutics, Inc. |
Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
|
US11815514B2
(en)
|
2015-12-04 |
2023-11-14 |
Juno Therapeutics, Inc. |
Methods and compositions related to toxicity associated with cell therapy
|
GB2545763A
(en)
|
2015-12-23 |
2017-06-28 |
Adverum Biotechnologies Inc |
Mutant viral capsid libraries and related systems and methods
|
EP4015536A1
(de)
|
2016-03-22 |
2022-06-22 |
Seattle Children's Hospital (DBA Seattle Children's Research Institute) |
Frühinterventionsverfahren zur vermeidung oder verbesserung von toxizität
|
JP2019513752A
(ja)
|
2016-04-07 |
2019-05-30 |
ケース ウエスタン リザーブ ユニバーシティ |
神経変性疾患を治療するためのtdp−43のミトコンドリア局在化阻害剤
|
US11351270B2
(en)
|
2016-06-07 |
2022-06-07 |
University Of Iowa Research Foundation |
Junctophilin-2 fragments and uses therefor
|
CA3025667A1
(en)
|
2016-06-08 |
2017-12-14 |
Intrexon Corporation |
Cd33 specific chimeric antigen receptors
|
CN110023327B
(zh)
|
2016-08-29 |
2024-02-27 |
韦恩州立大学 |
在具有改善光敏感性的通道视蛋白变体中突变的识别及其使用方法
|
EP3472198B1
(de)
|
2016-09-29 |
2020-03-04 |
H. Hoffnabb-La Roche Ag |
Verbessertes verfahren zur auswahl von polypeptidproduzierenden zellen
|
CN109790541B
(zh)
|
2016-09-29 |
2022-12-09 |
豪夫迈·罗氏有限公司 |
分析并优化基因编辑模块和递送方案的方法
|
CN110139873A
(zh)
|
2016-10-03 |
2019-08-16 |
朱诺治疗学股份有限公司 |
Hpv特异性结合分子
|
WO2018071873A2
(en)
|
2016-10-13 |
2018-04-19 |
Juno Therapeutics, Inc. |
Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
|
EP3535586A4
(de)
|
2016-11-01 |
2020-08-05 |
AnaptysBio, Inc. |
Gegen t-zell-immunglobulin und mucin-protein 3 (tim-3) gerichtete antikörper
|
AU2017354070A1
(en)
|
2016-11-01 |
2019-05-16 |
Anaptysbio, Inc. |
Antibodies directed against programmed death- 1 (PD-1)
|
WO2018102612A1
(en)
|
2016-12-02 |
2018-06-07 |
Juno Therapeutics, Inc. |
Engineered b cells and related compositions and methods
|
EP3548046A2
(de)
|
2016-12-03 |
2019-10-09 |
Juno Therapeutics, Inc. |
Verfahren und zusammensetzungen zur verwendung von therapeutischen t-zellen in kombination mit kinaseinhibitoren
|
AU2017375630B2
(en)
|
2016-12-12 |
2023-12-21 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells
|
AU2018205401A1
(en)
|
2017-01-09 |
2019-07-25 |
Tesaro, Inc. |
Methods of treating cancer with anti-TIM-3 antibodies
|
ES2945745T3
(es)
|
2017-01-09 |
2023-07-06 |
Tesaro Inc |
Métodos de tratamiento de cánceres con anticuerpos anti-PD-1
|
WO2018132494A1
(en)
|
2017-01-10 |
2018-07-19 |
Intrexon Corporation |
Modulating expression of polypeptides via new gene switch expression systems
|
CN110418802A
(zh)
|
2017-01-20 |
2019-11-05 |
朱诺治疗学有限公司 |
细胞表面缀合物及相关的细胞组合物和方法
|
CN110461335A
(zh)
|
2017-02-17 |
2019-11-15 |
弗雷德哈钦森癌症研究中心 |
用于治疗bcma相关癌症和自身免疫性失调的联合疗法
|
US10828330B2
(en)
|
2017-02-22 |
2020-11-10 |
IO Bioscience, Inc. |
Nucleic acid constructs comprising gene editing multi-sites and uses thereof
|
US20200191774A1
(en)
|
2017-02-27 |
2020-06-18 |
Juno Therapeutics, Inc. |
Compositions, articles of manufacture and methods related to dosing in cell therapy
|
MX2019012189A
(es)
|
2017-04-14 |
2020-12-10 |
Juno Therapeutics Inc |
Metodos para valorar la glucosilacion de la superficie celular.
|
NZ758485A
(en)
|
2017-04-27 |
2024-02-23 |
Juno Therapeutics Gmbh |
Oligomeric particle reagents and methods of use thereof
|
EA201992426A1
(ru)
|
2017-05-12 |
2020-05-06 |
Айон Чэннел Инновейшнз, Ллс |
Композиции и способы лечения синдрома идиопатической гиперактивности мочевого пузыря и гиперактивности детрузора
|
JP7486953B2
(ja)
|
2017-05-18 |
2024-05-20 |
ユーエムセー・ユトレヒト・ホールディング・ベー・フェー |
細胞標的化療法のための組成物および方法
|
CN111225675B
(zh)
|
2017-06-02 |
2024-05-03 |
朱诺治疗学股份有限公司 |
使用过继细胞疗法治疗的制品和方法
|
JP7379164B2
(ja)
|
2017-06-02 |
2023-11-14 |
ジュノー セラピューティクス インコーポレイテッド |
細胞療法に関連する毒性に関する製造物品および方法
|
CN110997920A
(zh)
|
2017-06-07 |
2020-04-10 |
英特拉克森公司 |
新型细胞标签的表达
|
JP7275104B2
(ja)
|
2017-08-09 |
2023-05-17 |
ジュノー セラピューティクス インコーポレイテッド |
遺伝子操作された細胞の組成物および関連組成物を産生するための方法
|
US11560549B2
(en)
|
2017-08-11 |
2023-01-24 |
Boehringer Ingelheim International Gmbh |
Integration sites in CHO cells
|
CN111148835A
(zh)
|
2017-10-02 |
2020-05-12 |
阿斯利康(瑞典)有限公司 |
用于增加蛋白产量的细胞系和方法
|
WO2019070541A1
(en)
|
2017-10-03 |
2019-04-11 |
Juno Therapeutics, Inc. |
HPV-SPECIFIC BINDING MOLECULES
|
WO2019089848A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Methods associated with tumor burden for assessing response to a cell therapy
|
AU2018360800A1
(en)
|
2017-11-01 |
2020-05-14 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for B-cell maturation antigen (BCMA)
|
BR112020008323A2
(pt)
|
2017-11-01 |
2020-11-03 |
Juno Therapeutics Inc |
anticorpos e receptores de antígenos quiméricos específicos para antígeno de maturação de células b
|
WO2019118937A1
(en)
|
2017-12-15 |
2019-06-20 |
Juno Therapeutics, Inc. |
Anti-cct5 binding molecules and methods of use thereof
|
EP3728309A2
(de)
|
2017-12-22 |
2020-10-28 |
Genentech, Inc. |
Gezielte integration von nukleinsäuren
|
EP3762010A4
(de)
|
2018-03-06 |
2022-04-06 |
Precigen, Inc. |
Hepatitis-b-impfstoffe und verwendungen davon
|
WO2019178267A2
(en)
|
2018-03-13 |
2019-09-19 |
University Of Iowa Research Foundation |
Inductive regeneration of the airway by transcriptional factor modulation of glandular myoepithelial stem cells
|
US11471489B2
(en)
|
2018-04-05 |
2022-10-18 |
Juno Therapeutics, Inc. |
T cell receptors and engineered cells expressing same
|
WO2019219979A1
(en)
|
2018-05-18 |
2019-11-21 |
Umc Utrecht Holding B.V. |
Compositions and methods for cell targeting therapies
|
EA202190469A1
(ru)
|
2018-08-09 |
2021-06-28 |
Джуно Терапьютикс, Инк. |
Способы оценки интегрированных нуклеиновых кислот
|
KR20210057730A
(ko)
|
2018-08-09 |
2021-05-21 |
주노 쎄러퓨티크스 인코퍼레이티드 |
조작 세포 및 이의 조성물 생성 방법
|
KR102559149B1
(ko)
|
2018-10-26 |
2023-07-24 |
에프. 호프만-라 로슈 아게 |
재조합효소 매개 카세트 교환을 이용한 다중특이적 항체 스크리닝 방법
|
SG11202104355SA
(en)
|
2018-10-31 |
2021-05-28 |
Juno Therapeutics Gmbh |
Methods for selection and stimulation of cells and apparatus for same
|
JP2022512913A
(ja)
|
2018-11-06 |
2022-02-07 |
ジュノー セラピューティクス インコーポレイテッド |
遺伝子操作されたt細胞を作製するための方法
|
US20220133849A1
(en)
|
2018-11-14 |
2022-05-05 |
Urovant Sciences Gmbh |
Compositions and methods for the treatment of smooth muscle dysfunction
|
EP3980544A1
(de)
|
2018-12-21 |
2022-04-13 |
F. Hoffmann-La Roche AG |
Gezielte integration von nukleinsäuren
|
MX2021011837A
(es)
|
2019-03-29 |
2021-10-22 |
Hoffmann La Roche |
Método para la generación de una célula que expresa el receptor neonatal de región de fragmento cristalizable (fcrn) mediante la integración dirigida de múltiples casetes de expresión en una organización definida.
|
CA3136737A1
(en)
|
2019-05-01 |
2020-11-05 |
Juno Therapeutics, Inc. |
Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
|
BR112021021200A2
(pt)
|
2019-05-01 |
2021-12-21 |
Juno Therapeutics Inc |
Células expressando um receptor quimérico de um locus cd247 modificado, polinucleotídeos relacionados e métodos
|
KR20220016925A
(ko)
|
2019-06-05 |
2022-02-10 |
아납티스바이오, 아이엔씨. |
Pd-1 작용제 및 이의 사용 방법
|
MX2021015538A
(es)
|
2019-06-19 |
2022-02-10 |
Hoffmann La Roche |
Metodo para la generacion de una celula que expresa un anticuerpo biespecifico bivalente mediante la integracion dirigida de multiples casetes de expresion en una organizacion definida.
|
EP3986928A1
(de)
|
2019-06-19 |
2022-04-27 |
F. Hoffmann-La Roche AG |
Verfahren zur erzeugung einer proteinexprimierenden zelle durch gezielte integration mittels cre-mrna
|
WO2020254352A1
(en)
|
2019-06-19 |
2020-12-24 |
F. Hoffmann-La Roche Ag |
Method for the generation of a trivalent antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
|
CA3140192A1
(en)
|
2019-06-19 |
2020-12-24 |
Johannes Auer |
Method for the generation of a multivalent, multispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
|
CN113993887A
(zh)
|
2019-06-19 |
2022-01-28 |
豪夫迈·罗氏有限公司 |
通过以限定的组织形式靶向整合多个表达盒来产生多价双特异性抗体表达细胞的方法
|
EP3990646A1
(de)
|
2019-06-26 |
2022-05-04 |
F. Hoffmann-La Roche AG |
Säugetierzelllinien mit sirt-1-gen-knockout
|
KR20220025806A
(ko)
|
2019-06-26 |
2022-03-03 |
제넨테크, 인크. |
핵산의 무작위 구성 표적화 통합
|
AU2020377043A1
(en)
|
2019-10-30 |
2022-06-02 |
Juno Therapeutics Gmbh |
Cell selection and/or stimulation devices and methods of use
|
KR20220100612A
(ko)
|
2019-11-05 |
2022-07-15 |
얀센 바이오테크 인코포레이티드 |
다발성 골수종의 bcma-표적화 car-t 세포 요법
|
AU2021211669A1
(en)
|
2020-01-21 |
2022-08-25 |
Bolt Biotherapeutics, Inc. |
Anti-PD-L1 antibodies
|
US20230069055A1
(en)
|
2020-01-21 |
2023-03-02 |
Bolt Biotherapeutics, Inc |
Anti-pd-l1 antibodies
|
AU2021262828A1
(en)
|
2020-05-01 |
2022-11-03 |
Bolt Biotherapeutics, Inc. |
Anti-Dectin-2 antibodies
|
WO2021231661A2
(en)
|
2020-05-13 |
2021-11-18 |
Juno Therapeutics, Inc. |
Process for producing donor-batched cells expressing a recombinant receptor
|
CN116096907A
(zh)
|
2020-06-24 |
2023-05-09 |
基因泰克公司 |
核酸的靶向整合
|
WO2021260186A1
(en)
|
2020-06-26 |
2021-12-30 |
Juno Therapeutics Gmbh |
Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
|
CN118201956A
(zh)
|
2020-07-24 |
2024-06-14 |
豪夫迈·罗氏有限公司 |
用于表达抗体-多聚体-融合物的方法
|
WO2022026832A1
(en)
|
2020-07-30 |
2022-02-03 |
Anaptysbio, Inc. |
Anti-interleukin 36 receptor (il-36r) therapy for ichthyosis
|
WO2022026829A1
(en)
|
2020-07-30 |
2022-02-03 |
Anaptysbio, Inc. |
Anti-interleukin 36 receptor (il-36r) therapy for skin toxicity
|
US20220154207A1
(en)
|
2020-09-24 |
2022-05-19 |
Hoffmann-La Roche Inc. |
Mammalian cell lines with gene knockout
|
KR20230085170A
(ko)
|
2020-10-15 |
2023-06-13 |
에프. 호프만-라 로슈 아게 |
동시 유전자 활성화를 위한 핵산 구조체
|
IL302046A
(en)
|
2020-10-15 |
2023-06-01 |
Hoffmann La Roche |
Nucleic acid structures for va RNA transcription
|
JP2023546713A
(ja)
|
2020-10-23 |
2023-11-07 |
アナプティスバイオ インコーポレイティッド |
B及びtリンパ球アテニュエータ(btla)調節因子及びその使用方法
|
EP4240756A1
(de)
|
2020-11-04 |
2023-09-13 |
Juno Therapeutics, Inc. |
Zellen zur expression eines chimären rezeptors aus einem modifizierten invarianten kettenlocus der cd3-immunglobulin-superfamilie und zugehörige polynukleotide und verfahren
|
WO2022116086A1
(en)
|
2020-12-03 |
2022-06-09 |
Janssen Biotech, Inc. |
Bcma-targeted car-t cell therapy for multiple myeloma
|
JP2024501662A
(ja)
|
2020-12-22 |
2024-01-15 |
エフ. ホフマン-ラ ロシュ アーゲー |
Xbp1を標的とするオリゴヌクレオチド
|
AU2022241654A1
(en)
|
2021-03-22 |
2023-09-28 |
Juno Therapeutics, Inc. |
Methods of determining potency of a therapeutic cell composition
|
CN117916256A
(zh)
|
2021-05-06 |
2024-04-19 |
朱诺治疗学有限公司 |
用于刺激和转导t细胞的方法
|
EP4148067A1
(de)
|
2021-09-08 |
2023-03-15 |
F. Hoffmann-La Roche AG |
Verfahren zur expression einer antikörper-multimer-fusion
|
WO2023077343A1
(en)
|
2021-11-04 |
2023-05-11 |
Janssen Biotech, Inc. |
Bcma-targeted car-t cell therapy for multiple myeloma
|
AU2022381186A1
(en)
|
2021-11-04 |
2024-05-16 |
Janssen Biotech, Inc. |
Bcma-targeted car-t cell therapy for multiple myeloma
|
WO2023122246A1
(en)
|
2021-12-22 |
2023-06-29 |
Genentech, Inc. |
Multi-vector recombinase mediated cassette exchange
|
WO2023137460A1
(en)
|
2022-01-14 |
2023-07-20 |
Saccharo, Inc. |
De-n-acetylated polysialic acid (dpsa) binding agent and method of using same
|
US20230270786A1
(en)
|
2022-02-28 |
2023-08-31 |
Janssen Biotech, Inc. |
Bcma-targeted car-t cell therapy for multiple myeloma
|
WO2023198685A1
(en)
|
2022-04-13 |
2023-10-19 |
F. Hoffmann-La Roche Ag |
Method for determining aav genomes
|
WO2023202967A1
(en)
|
2022-04-19 |
2023-10-26 |
F. Hoffmann-La Roche Ag |
Improved production cells
|
WO2023212611A1
(en)
|
2022-04-27 |
2023-11-02 |
Anaptysbio, Inc. |
B and t lymphocyte attenuator (btla) modulators and method of using same
|
WO2023213969A1
(en)
|
2022-05-05 |
2023-11-09 |
Juno Therapeutics Gmbh |
Viral-binding protein and related reagents, articles, and methods of use
|
WO2023232961A1
(en)
|
2022-06-03 |
2023-12-07 |
F. Hoffmann-La Roche Ag |
Improved production cells
|
WO2023232922A1
(en)
|
2022-06-03 |
2023-12-07 |
F. Hoffmann-La Roche Ag |
Method for producing recombinant aav particles
|
WO2024006960A1
(en)
|
2022-06-29 |
2024-01-04 |
Juno Therapeutics, Inc. |
Lipid nanoparticles for delivery of nucleic acids
|
WO2024102760A2
(en)
|
2022-11-07 |
2024-05-16 |
Anaptysbio, Inc. |
Cd 122 binding agents and method of using same
|
WO2024100604A1
(en)
|
2022-11-09 |
2024-05-16 |
Juno Therapeutics Gmbh |
Methods for manufacturing engineered immune cells
|
WO2024107879A1
(en)
|
2022-11-15 |
2024-05-23 |
Genentech, Inc. |
Combined transposon-mediated integration and targeted integration of nucleic acids into host cells
|
WO2024110426A1
(en)
|
2022-11-23 |
2024-05-30 |
F. Hoffmann-La Roche Ag |
Method for increasing recombinant protein expression
|
WO2024124132A1
(en)
|
2022-12-09 |
2024-06-13 |
Juno Therapeutics, Inc. |
Machine learning methods for predicting cell phenotype using holographic imaging
|